L01EX03 • pazopanib • Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Other protein kinase inhibitors
Pazopanib is a medication used for the treatment of certain types of cancer, such as advanced renal cell carcinoma and soft tissue sarcoma. It is a tyrosine kinase inhibitor that blocks the growth of blood vessels supplying tumors, thereby slowing cancer progression.
The medication is taken orally, usually once daily, and should be used as directed by your doctor. Regular check-ups are important to monitor the effectiveness of the treatment and any potential side effects.
Side effects may include nausea, diarrhea, high blood pressure, fatigue, or changes in liver function. In rare cases, severe reactions such as liver failure or bleeding may occur.
Patients should inform their doctor about any other medications being used or pre-existing conditions to ensure the safe use of pazopanib.
Substance: pazopanib
Date of last drug list: 01-09-2021
Commercial code: W67887006
Concentration: 200mg
Pharmaceutical form: tablets
Quantity: 120
Product type: generic
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: ALVOGEN MALTA (OUT-LICENSING) LTD./AMOL LTD. - MALTA
Holder: ADALVO LIMITED - MALTA
Number: 13923/2021/06
Shelf life: 30 months